Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction

Heart failure with preserved ejection fraction (HFpEF) is an unsolved and growing concern in cardiovascular medicine. While no treatment options that improve prognosis in HFpEF patients has been established so far, SGLT2 inhibitors (SGLT2i) are currently being investigated for the treatment of HFpEF...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Steffen Pabel, Nazha Hamdani, Jagdeep Singh, Samuel Sossalla
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	heart failure HFpEF—heart failure with preserved ejection fraction SGLT2 inhibitors diastolic function inflammation oxidative stress Physiology QP1-981
Acceso en línea:	https://doaj.org/article/31eba08da8b04904b15c4c805768ab11
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:31eba08da8b04904b15c4c805768ab11
record_format	dspace
spelling	oai:doaj.org-article:31eba08da8b04904b15c4c805768ab112021-11-05T07:50:59ZPotential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction1664-042X10.3389/fphys.2021.752370https://doaj.org/article/31eba08da8b04904b15c4c805768ab112021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphys.2021.752370/fullhttps://doaj.org/toc/1664-042XHeart failure with preserved ejection fraction (HFpEF) is an unsolved and growing concern in cardiovascular medicine. While no treatment options that improve prognosis in HFpEF patients has been established so far, SGLT2 inhibitors (SGLT2i) are currently being investigated for the treatment of HFpEF patients. SGLT2i have already been shown to mitigate comorbidities associated with HFpEF such as type 2 diabetes and chronic renal disease, however, more recently there has been evidence that they may also directly improve diastolic function. In this article, we discuss some potential beneficial mechanisms of SGLT2i in the pathophysiology of HFpEF with focus on contractile function.Steffen PabelNazha HamdaniNazha HamdaniJagdeep SinghSamuel SossallaSamuel SossallaFrontiers Media S.A.articleheart failureHFpEF—heart failure with preserved ejection fractionSGLT2 inhibitorsdiastolic functioninflammationoxidative stressPhysiologyQP1-981ENFrontiers in Physiology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	heart failure HFpEF—heart failure with preserved ejection fraction SGLT2 inhibitors diastolic function inflammation oxidative stress Physiology QP1-981
spellingShingle	heart failure HFpEF—heart failure with preserved ejection fraction SGLT2 inhibitors diastolic function inflammation oxidative stress Physiology QP1-981 Steffen Pabel Nazha Hamdani Nazha Hamdani Jagdeep Singh Samuel Sossalla Samuel Sossalla Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
description	Heart failure with preserved ejection fraction (HFpEF) is an unsolved and growing concern in cardiovascular medicine. While no treatment options that improve prognosis in HFpEF patients has been established so far, SGLT2 inhibitors (SGLT2i) are currently being investigated for the treatment of HFpEF patients. SGLT2i have already been shown to mitigate comorbidities associated with HFpEF such as type 2 diabetes and chronic renal disease, however, more recently there has been evidence that they may also directly improve diastolic function. In this article, we discuss some potential beneficial mechanisms of SGLT2i in the pathophysiology of HFpEF with focus on contractile function.
format	article
author	Steffen Pabel Nazha Hamdani Nazha Hamdani Jagdeep Singh Samuel Sossalla Samuel Sossalla
author_facet	Steffen Pabel Nazha Hamdani Nazha Hamdani Jagdeep Singh Samuel Sossalla Samuel Sossalla
author_sort	Steffen Pabel
title	Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
title_short	Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
title_full	Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
title_fullStr	Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
title_full_unstemmed	Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
title_sort	potential mechanisms of sglt2 inhibitors for the treatment of heart failure with preserved ejection fraction
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/31eba08da8b04904b15c4c805768ab11
work_keys_str_mv	AT steffenpabel potentialmechanismsofsglt2inhibitorsforthetreatmentofheartfailurewithpreservedejectionfraction AT nazhahamdani potentialmechanismsofsglt2inhibitorsforthetreatmentofheartfailurewithpreservedejectionfraction AT nazhahamdani potentialmechanismsofsglt2inhibitorsforthetreatmentofheartfailurewithpreservedejectionfraction AT jagdeepsingh potentialmechanismsofsglt2inhibitorsforthetreatmentofheartfailurewithpreservedejectionfraction AT samuelsossalla potentialmechanismsofsglt2inhibitorsforthetreatmentofheartfailurewithpreservedejectionfraction AT samuelsossalla potentialmechanismsofsglt2inhibitorsforthetreatmentofheartfailurewithpreservedejectionfraction
_version_	1718444459683741696

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction

Ejemplares similares